US regulatory status: approved. Molecular target: Phosphodiesterase 4.
- Target
- Phosphodiesterase 4
- Mechanism
- Phosphodiesterase 4 inhibitor
biotech · Neuroblastoma · Hyperinflammation, Sepsis · AXIM
AXIM Biotechnologies
AXIM BIOTECHNOLOGIES, INC.
AXIM Biotechnologies drug portfolio — 52 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
18 East 50th Street, 5 Floor, New York, NY 10022, US HQ
2011 Founded
7 Employees
Public company Type
AXIM · NYSE Ticker
Company details
- Status
- Public
- HQ
- 18 East 50th Street, 5 Floor, New York, NY 10022, US
- Founded
- 2011
- Employees
- 7
- Programs
- 20
- Drugs
- 52
- Patents
- 138
AXIM Biotechnologies pipeline
Portfolio lens on 52 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
AXIM Biotechnologies drug portfolio — 52 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
anakinra
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Interleukin-1 receptor type 1.
- Target
- Interleukin-1 receptor type 1
- Mechanism
- Interleukin-1 receptor antagonist
-
Development asset linked to AXIM Biotechnologies in public FDA and regional records.
-
aprepitant
Alimentary tract and metabolism (A04)US regulatory status: approved. Molecular target: Substance-P receptor.
- Target
- Substance-P receptor
- Mechanism
- Neurokinin 1 receptor antagonist
-
brigatinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: ALK tyrosine kinase receptor.
- Target
- ALK tyrosine kinase receptor
- Mechanism
- ALK tyrosine kinase receptor inhibitor
-
Development asset linked to AXIM Biotechnologies in public FDA and regional records.
-
Development asset linked to AXIM Biotechnologies in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to AXIM Biotechnologies in public FDA and regional records.
-
Development asset linked to AXIM Biotechnologies in public FDA and regional records.
-
Development asset linked to AXIM Biotechnologies in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
clofarabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
cytarabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
dasatinib (anhydrous)
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in AXIM Biotechnologies's portfolio. Molecular target: Bcr/Abl fusion protein.
- Target
- Bcr/Abl fusion protein
- Mechanism
- Bcr/Abl fusion protein inhibitor
-
Development asset linked to AXIM Biotechnologies in public FDA and regional records.
-
doxorubicin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in AXIM Biotechnologies's portfolio. Mechanism: DNA topoisomerase II alpha inhibitor.
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
US regulatory status: approved. Molecular target: DNA topoisomerase II.
- Target
- DNA topoisomerase II
- Mechanism
- DNA topoisomerase II inhibitor
-
Development asset linked to AXIM Biotechnologies in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA polymerase (alpha/delta/epsilon).
- Target
- DNA polymerase (alpha/delta/epsilon)
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
fosaprepitant
Alimentary tract and metabolism (A04)Alimentary tract and metabolism (A04) compound in AXIM Biotechnologies's portfolio. Mechanism: Neurokinin 1 receptor antagonist.
- Mechanism
- Neurokinin 1 receptor antagonist
-
US regulatory status: approved. Molecular target: Substance-P receptor.
- Target
- Substance-P receptor
- Mechanism
- Neurokinin 1 receptor antagonist
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to AXIM Biotechnologies in public FDA and regional records.
-
Development asset linked to AXIM Biotechnologies in public FDA and regional records.
-
Development asset linked to AXIM Biotechnologies in public FDA and regional records.
-
US regulatory status: approved.
-
ioflupane (123i)
Various (V09)Various (V09) compound in AXIM Biotechnologies's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
Development asset linked to AXIM Biotechnologies in public FDA and regional records.
-
Development asset linked to AXIM Biotechnologies in public FDA and regional records.
-
Development asset linked to AXIM Biotechnologies in public FDA and regional records.
-
quizartinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in AXIM Biotechnologies's portfolio. Molecular target: Macrophage colony-stimulating factor 1 receptor.
- Target
- Macrophage colony-stimulating factor 1 receptor
- Mechanism
- Platelet-derived growth factor receptor inhibitor
-
ruxolitinib
Dermatologicals (D11)US regulatory status: approved. Mechanism: Tyrosine-protein kinase JAK2 inhibitor.
- Mechanism
- Tyrosine-protein kinase JAK2 inhibitor
-
US regulatory status: approved.
-
Development asset linked to AXIM Biotechnologies in public FDA and regional records.
-
Development asset linked to AXIM Biotechnologies in public FDA and regional records.
-
Development asset linked to AXIM Biotechnologies in public FDA and regional records.
-
Development asset linked to AXIM Biotechnologies in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Diagnostic.
- Mechanism
- Diagnostic
-
US regulatory status: approved.
-
US regulatory status: approved.
-
US regulatory status: approved.
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
Development asset linked to AXIM Biotechnologies in public FDA and regional records.
-
tovorafenib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: RAF serine/threonine protein kinase.
- Target
- RAF serine/threonine protein kinase
- Mechanism
- RAF serine/threonine protein kinase inhibitor
-
Development asset linked to AXIM Biotechnologies in public FDA and regional records.
-
venetoclax
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Apoptosis regulator Bcl-2.
- Target
- Apoptosis regulator Bcl-2
- Mechanism
- Apoptosis regulator Bcl-2 inhibitor
-
Development asset linked to AXIM Biotechnologies in public FDA and regional records. Mechanism: Tubulin inhibitor.
- Mechanism
- Tubulin inhibitor
-
US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
US regulatory status: approved.